How do you pay?

How to pay the least

Ask for the cash price

Fabhalta

We didn’t find one.

  1. Ask your pharmacy for Fabhalta’s cash price, and one or two other pharmacies too.
  2. Fabhalta’s savings card works only with insurance from a job or one you bought.

Free from the maker, if you qualify Novartis Patient Assistance Foundation (NPAF). Patients must have a household income of less than or equal to $81,760 (for a household size of two) to be considered for NPAF. Or call 1-800-277-2254.

See if you qualify 

Compare every option

Question
Brand nameFabhalta
Authorized genericiptacopan
Regular genericiptacopan
What you’d pay
Cash priceAsk the pharmacy
Not soldThere isn’t one
Not soldNone found
Same as Fabhalta?
The original
–
–

Brand nameThe maker’s card

Novartis Patient Support Co-Pay Plus

Savings card from Novartis

No insuranceNeeds insuranceNo cash price listed.
Insurance · as little as $0 a fill

The card takes up to $20,000 a year off your co-pay.

Sign up on fabhalta.com 

Or call 1-833-993-2242.

In the maker’s words

“Eligible patients with private insurance may pay as little as $0…”

From the maker’s offer on fabhalta.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Maker’s card or discount card?

A discount card like GoodRx lowers the pharmacy’s cash price, but for a brand-name drug that price often stays high. Compare it with the maker’s card above. You can usually use one or the other on a fill, not both.

Authorized genericNot sold

There isn’t one. An authorized generic is Fabhalta itself, from the same company, sold without the brand name, and usually for less. For now Fabhalta is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

We didn’t find one. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

FABHALTA is a complement factor B inhibitor, indicated for:

  • the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH).
  • slowing kidney function decline in adults with primary immunoglobulin A nephropathy (IgAN) at risk of disease progression.
  • the treatment of adults with complement 3 glomerulopathy (C3G), to reduce proteinuria.

Source: the FDA label for Fabhalta (Novartis Pharmaceuticals Corporation), July 16, 2026. Full label on DailyMed 

Good to know